GlassScriptPhysician profile
Clay Gruesbeck
NPI 1669451019
$1,034.02
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $70.47 · 2021: $233 · 2022: $186.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $255.67 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $227.99 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $130.68 | 2019 | |
| Allergan, INC. | $64.01 | 2019-2020 | |
| Abbvie INC. | $62.08 | 2021-2022 | |
| Livanova USA, INC. | $39.80 | 2019 | |
| Ironshore Pharmaceuticals INC. | $36.81 | 2019 | |
| Merck Sharp & Dohme LLC | $23.15 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.11 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.63 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.88 | 2019 | |
| Sebela Pharmaceuticals INC. | $16.44 | 2019 | |
| Gilead Sciences, INC. | $16.23 | 2019 | |
| Shire North American Group INC | $15.99 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $15.87 | 2022 | |
| Astellas Pharma US INC | $14.61 | 2019 | |
| Glaxosmithkline, LLC. | $12.29 | 2021 | |
| Lilly USA, LLC | $11.51 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clay Gruesbeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.